Celcuity
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients tre...
Latest News
8 days ago · globenewswire.com
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast CancerMINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review its supplemental New Drug Application (“sNDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of June 25, 2027.
8 days ago · seekingalpha.com
Celcuity Inc. (CELC) Q3 2026 Earnings Call TranscriptCelcuity Inc. ( CELC ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Jodi Sievers - Head of Investor Relations & Corporate Communications Brian Sullivan - Co-Founder, Chairman & CEO Vicky Hahne - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Tara Bancroft - TD Cowen, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Gil Blum - Needham & Company, LLC, Research Division Daniel Bronder - Cantor Fitzgerald & Co., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Oliver McCammon - LifeSci Capital, LLC, Research Division Kalpit Patel - Wolfe Research, LLC Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2026 Financial Results Call and Webcast. [Operator Instructions] This call is being recorded on Thursday, November 5, 2026.
11 days ago · marketbeat.com
What Celcuity (CELC) Said on Its Q3 Earnings CallCelcuity NASDAQ: CELC reported a wider third-quarter loss as it prepared to commercialize its breast cancer treatment REVTORPYK, while executives said early orders and insurance coverage pointed to an encouraging launch.
14 days ago · globenewswire.com
Celcuity To Participate in Upcoming Investor ConferencesMINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
18 days ago · seekingalpha.com
Celcuity: Stronger Clinical Evidence, Much Lower ValuationCelcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. REVTORPYK demonstrated strong efficacy and safety, especially versus existing PI3K-targeted regimens, but faces competition from established oral drugs like Truqap. Management targets $2.5 billion peak sales, but base case models suggest substantial upside even at $1.2 billion with current US-only assumptions.
19 days ago · globenewswire.com
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference CallMINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update.
24 days ago · globenewswire.com
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases
25 days ago · globenewswire.com
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone
1 month ago · globenewswire.com
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer Poster presentation of sub-group analyses from the Phase 1b trial of gedatolisib plus darolutamide in patients with mCRPC MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that a late breaking rapid oral presentation and three poster presentations will be featured at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2026 being held October 23-27, 2026, in Madrid, Spain. Data from its clinical trials of gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) locally advanced or metastatic breast cancer (“ABC”) and metastatic castration-resistant prostate cancer (“mCRPC”) will be presented.
2 months ago · globenewswire.com
Celcuity Appoints David Gryska To Its Board Of DirectorsMr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CELC